Genvor Reports Reduced Net Loss and Decreased Operating Expenses for December 2025 Quarter

Genvor Incorporated reported its financial results for the three months ending December 31, 2025, revealing a net loss of $576,280, or $0.02 per share, a significant reduction from the net loss of $5,001,251, or $0.24 per share, recorded in the same period the previous year. The company did not generate any revenue during this quarter, maintaining the same status as the prior year. Total operating expenses decreased to $562,655 from $4,997,414, primarily due to a substantial reduction in compensation and related benefits expenses, which fell by 94.4% to $272,985, largely attributed to a decrease in stock-based compensation.

In terms of financial position, Genvor's total current assets increased to $145,739 as of December 31, 2025, compared to $45,822 at the end of September 2025. This increase was driven by a rise in cash reserves, which reached $103,580, up from $37,231. Total current liabilities also decreased to $1,205,059 from $1,358,204, resulting in a working capital deficit that improved by 19% to $1,059,320. The company attributed these changes to the conversion of a convertible note payable and accrued compensation into shares of common stock, as well as a reduction in accounts payable and accrued expenses.

Strategically, Genvor has been focusing on its agricultural biotechnology initiatives, particularly its proprietary BioCypher Algorithm for peptide technology aimed at sustainable crop protection. The company has engaged in partnerships and collaborations, including a notable Golden Ticket award from Bayer AG, which provides access to laboratory resources and mentorship to accelerate the development of its peptide-based technologies. Genvor is also exploring international collaborations in animal health research and is committed to advancing non-GMO product development.

Operationally, Genvor's employee headcount remains stable, with ongoing efforts to enhance its research and development capabilities. The company has been actively participating in biotechnology conferences and engaging with USDA partners to further its studies on seed traits in corn. Despite these advancements, Genvor's management has expressed concerns regarding its ability to continue as a going concern, citing the need for additional capital to support operations and the uncertainty surrounding future revenue generation. The company plans to pursue further financing through equity or debt offerings, although there are no guarantees of success in these endeavors.